论文部分内容阅读
目的观察瑞舒伐他汀钙片对原发性高胆固醇血症患者的临床疗效及其对患者血清超敏C反应蛋白(hs-CRP)、可溶性血管细胞黏附因子~(-1)(s VCAM~(-1))的影响。方法将86例原发性高胆固醇血症患者分为试验组与对照组,每组43例。对照组患者给予阿托伐他汀钙片10 mg·d~(-1),口服;试验组患者给予瑞舒伐他汀钙片10 mg·d~(-1),口服。2组患者均治疗8周。比较2组患者的临床疗效、血脂水平及血清hs-CRP、s VCAM~(-1)水平。结果治疗后,试验组总有效率为95.35%(41/43例),对照组为79.07%(34/43例,P<0.05)。治疗后,试验组血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)分别为(4.38±0.89),(1.54±0.79),(2.23±0.82)mmol·L~(-1),对照组分别为(4.79±0.87),(1.90±0.83),(2.61±0.89)mmol·L~(-1),差异有统计学意义(P<0.05)。治疗后,试验组和对照组hs-CRP分别为(4.83±1.13),(5.12±1.78)mg·L~(-1),s VCAM~(-1)分别为(0.37±0.15),(0.39±0.13)mg·L~(-1),差异有统计学意义(P<0.05)。2组患者主要的药物不良反应为便秘、腹痛、恶心,试验组和对照组药物不良反应发生率分别为11.63%(5/43例),13.95%(6/43例),差异无统计学意义(P>0.05)。结论瑞舒伐他汀钙片治疗原发性高胆固醇血症有较好的临床疗效和安全性。
Objective To observe the clinical efficacy of rosuvastatin calcium tablets in patients with primary hypercholesterolemia and its effect on the serum levels of hs-CRP, sVCAM ~ (-1)). Methods 86 patients with primary hypercholesterolemia were divided into experimental group and control group, with 43 cases in each group. Patients in the control group received atorvastatin calcium 10 mg · d -1 orally, and patients in the test group received rosuvastatin calcium 10 mg · d -1 orally. Two groups of patients were treated for 8 weeks. The clinical efficacy, blood lipid level and serum hs-CRP, s VCAM -1 levels were compared between the two groups. Results After treatment, the total effective rate was 95.35% (41/43 cases) in the experimental group and 79.07% (34/43 cases, P <0.05) in the control group. After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) were 4.38 ± 0.89, 1.54 ± 0.79 and 2.23 ± 0.82 mmol · (-1) and (4.79 ± 0.87), (1.90 ± 0.83) and (2.61 ± 0.89) mmol·L -1 respectively in the control group (P <0.05). After treatment, the hs-CRP levels in the experimental and control groups were (4.83 ± 1.13) and (5.12 ± 1.78) mg · L -1, respectively, and the VCAM -1 sVCAM -1 were 0.37 ± 0.15 and 0.39 ± 0.13) mg · L ~ (-1), the difference was statistically significant (P <0.05). The adverse reactions of the two groups were mainly constipation, abdominal pain and nausea. The incidences of adverse drug reactions in the two groups were 11.63% (5/43 cases) and 13.95% (6/43 cases), respectively, with no significant difference (P> 0.05). Conclusion Rosuvastatin calcium treatment of primary hypercholesterolemia have good clinical efficacy and safety.